Hepatitis C Virus
Peregrine Pharmaceuticals Announces Registered Direct Offering of $22.5 Million in Common Stock
Published in Healthcare Mergers, Acquisitions and Ventures Week, July 21st, 2007
Under the terms of the transaction, Peregrine will receive approximately $22.5 million in gross proceeds in exchange for up to 30,000,000 shares of its common stock. Net proceeds following the payment of sales commissions and other expenses of the offering are expected to be approximately $20.9 million....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- A2LA
A2LA Adds Information Technology Testing to Its Fields of Accreditation - Accelrys
Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference - Accentia Biopharmaceuticals, Inc.
Accentia Biopharmaceuticals Appoints Pharmaceutical and Medical Device Veteran to Board of Directors - Acorda Therapeutics
Acorda Therapeutics Joins Russell 3000 Index - Acorda Therapeutics
Acorda Therapeutics' President and CEO Ron Cohen, M.D. Named Ernst & Young Entrepreneur of the Year 2007 Award Winner in the Metro New York Area - Acorda Therapeutics, Inc.
Acorda Therapeutics Announces Exercise of Option by Underwriters - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
